Hardtech fellowship names 11 innovators to inaugural Houston cohort

ready for activation

The inaugural Activate Houston cohort has 11 fellows across energy, materials, life sciences, space, and other sectors. Photo via activate.org

A national hardtech-focused organization has named its 2024 batch of innovators, which includes the inaugural Houston-based cohort.

Activate named 62 fellows and 50 companies for is latest class, which spans Berkley, California — where the organization is based, Boston, New York, and Houston. Additionally, Activate Anywhere, the program's virtual and remote cohort, was named. According to Activate, it received over 1,000 applicants.

“People, not ideas alone, move the world forward. It is through the drive and determination of brilliant scientists and engineers that we are witnessing true progress,” says Activate CEO Cyrus Wadia in a news release. “Our current Activate Fellows and alumni are already pioneering innovative solutions that make a measurable difference. We’re thrilled to support the next 62 visionaries who will lead the charge in addressing our most urgent issues through groundbreaking science and technology.”

It's the first year Activate has hosted a Houston-based cohort. The organization initially announced its expansion early last year. The inaugural cohort has 11 fellows across energy, materials, life sciences, space, and other sectors.

The named Houston fellows selected for the 2024 class include:

  • Krish Mehta, founder and CEO of Phoenix Materials, a company that decarbonizes concrete using industrial waste.
  • Gabriel Cossio, founder and CEO of Nanoscale Labs, which is developing a high-throughput and low-cost nanomanufacturing system.
  • Matthew McDermott, founder and CEO of Refound Materials, a materials technology company developing more efficient synthesis recipes for accelerated materials discovery.
  • Alec Ajnsztajn, founder and CEO of Coflux Purification, a company that's creating a product that allows industries and water providers to cheaply remove forever chemicals to provide safe drinking water at a fraction of current energy use.
  • Ryan DuChanois and Yang Xia , co-founders of Solidec, a Houston-based startup redefining chemical manufacturing.
  • Meagan Pitcher, co-founder and CEO of Bairitone Health, which brings advanced imaging diagnostics into the home environment.
  • Wei Meng, co-founder and CEO of LumiStrain, a startup offering novel technology for mechanical strain mapping.
  • Sonia Dagan of Atolla Tech, which is developing a lidar and machine-learning algorithm for identifying and quantifying airborne insects.
  • Rodrigo Alvarez-Icaza, founder and CEO of Elysium Robotics, a company that's replacing electric motors with muscle-like actuators to enable massive deployment of highly capable and low-cost robotic systems.
  • Blake Herren, CEO and Co-founder of Raven Space Systems, which is modernizing composite manufacturing with 3D printing and Industry 4.0 solutions to build the factories of the future.

------

This article originally ran on EnergyCapital.

From Your Site Articles
Activate announced Cyrus Wadia as its new CEO and opened its 2024 applications. Photo courtesy of Activate

New-to-Houston hardtech accelerator names new CEO, opens applications

apply now

A national organization that helps accelerate scientists into entrepreneurs has named its new CEO in the same week that applications opened for its 2024 cohort.

This week, Activate announced Cyrus Wadia as CEO of the organization. Based California, Activate recently expanded to Houston. The two-year accelerator provides funding and support for its selected cohorts.

Wadia most recently served as director of worldwide product sustainability at Amazon. He also oversaw sustainable business and innovation at Nike and was appointed assistant director of clean energy and materials R&D at the White House Office of Science and Technology Policy under President Barack Obama.

"I’m thrilled to join this incredible team at such an exciting moment for the organization. Because of Activate, scientists are designing new products, accelerating the creation of new businesses, and becoming leaders who will transform our future," Wadia says in the news release. "I look forward to building on this momentum to expand the role science leadership plays in solving society’s most pressing issues.”

Wadia’s new role takes effect on October 16. Todd Johnson has served as interim CEO for the past year, and he will return to his role on Activate’s board of directors with the transition. The program's led locally by Jeremy Pitts, managing director for Activate Houston, who was named to the role last month.

The announcement came just a few days before Activate opened applications for its 2024 program — which will be the first year to have a Houston cohort. Applications are open until October 17 across Activate's five programs. The two-year, hardtech-focused program was founded in Berkeley, California, in 2015 and expanded to Boston and New York before launching its virtual program, Activate Anywhere.

“Activate’s recruitment process is crucial, as it centers around finding scientists directly interested in solving urgent problems,” Pitts says. “Activate fellows are turning their technical breakthroughs into businesses that can help industries like manufacturing, energy, chemicals, computing, and agriculture, to meet their decarbonization and resiliency goals.”

------

A version of this article originally ran on EnergyCapitalHTX.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.

View All Listings